¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"symptomatic hypertension"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ocular hypertension indicator
    °í¾È¾ÐÁöÇ¥
  • orthostatic hypertension
    ±â¸³°íÇ÷¾Ð
  • portal hypertension
    ¹®¸Æ°íÇ÷¾Ð
  • pregnancy-induced hypertension
    ÀӽŰíÇ÷¾Ð
  • primary hypertension
    ¿ø¹ß¼º°íÇ÷¾Ð
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð, ÇãÆÄµ¿¸Æ°íÇ÷¾Ð
  • renal hypertension
    ÄáÆÏ°íÇ÷¾Ð, ½ÅÀ强°íÇ÷¾Ð
  • renovascular hypertension
    ÄáÆÏÇ÷°ü°íÇ÷¾Ð, ½ÅÀåÇ÷°ü°íÇ÷¾Ð
  • stasis hypertension
    ¿ïÇ÷°íÇ÷¾Ð
  • secondary hypertension
    ÀÌÂ÷°íÇ÷¾Ð
  • sinusoidal hypertension
    ±¼Ç÷°ü°íÇ÷¾Ð
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • orthostatic hypertension
    ±â¸³°íÇ÷¾Ð
  • portal hypertension
    ¹®¸Æ°íÇ÷¾Ð
  • primary hypertension
    (¢¡essential hypertension) º»Å°íÇ÷¾Ð
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð, ÇãÆÄ°íÇ÷¾Ð
  • rebound hypertension
    ¹Ýµ¿°íÇ÷¾Ð
  • red hypertension
    È«Á¶°íÇ÷¾Ð, ºÓÀº°íÇ÷¾Ð
  • renal hypertension
    ÄáÆÏ°íÇ÷¾Ð
  • renovascular hypertension
    ÄáÆÏÇ÷°ü°íÇ÷¾Ð
  • secondary hypertension
    ÀÌÂ÷°íÇ÷¾Ð
  • stasis hypertension
    ¿ïÇ÷°íÇ÷¾Ð
  • ocular hypertension indicator
    ¾È±¸°íÇ÷¾ÐÁöÇ¥
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ
  • primary hypertension
    ¿ø¹ß(¼º) °íÇ÷¾ÐÁõ (¡­ÍÔúìäâñø).
  • primary hypertension
    ¿ø¹ß(¼º) °íÇ÷¾ÐÁõ(ê«Û¡(àõ) ÍÔúìäâñø)
  • primary pulmonary hypertension
    ¿ø¹ß(¼º) Æó°íÇ÷¾ÐÁõ(¡­øËÍÔúìäâñø).
  • primary pulmonary hypertension
    ¿ø¹ß(¼º) Æó°íÇ÷¾ÐÁõ(ê«Û¡(àõ) øËÍÔúìäâñø)
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð, Æó°íÇ÷¾ÐÁõ.
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð(øËÔÑØæÍÔúìäâ), Æó°íÇ÷¾ÐÁõ(øËÍÔúìäâñø)
  • red hypertension
    È«Á¶¼º °íÇ÷¾ÐÁõ(ûõðÍàõÍÔúìäâñø).
  • red hypertension
    È«Á¶¼º °íÇ÷¾ÐÁõ(ûõðÍàõÍÔúìäâñø)
  • renal hypertension
    ½Å¼º °íÇ÷¾Ð(ãìàõÍÔúìäâ).
  • renal hypertension
    ½Å¼º °íÇ÷¾Ð(¡­ÍÔúìäâ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • accelerated hypertension
    °¡¼Ó¼º °íÇ÷¾Ð.
  • adrenal hypertension
    ºÎ½Å¼º °íÇ÷¾ÐÁõ(¡­ÍÔúìäâñø).
  • arterial hypertension
    µ¿¸Æ(¼º) °íÇ÷¾Ð(Áõ).
  • borderline hypertension
    °æ°è¿ª°íÇ÷¾Ð.
  • borderline hypertension
    °æ°è¿ª °íÇ÷¾Ð(ÌÑÍ£æ´ ÍÔúìäâ).
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð(¡­ÍÔúìäâ).
  • essential hypertension
    º»Å¼º °íÇ÷¾Ð.
  • essential hypertension
    º»Å¼º(Üâ÷¾àõ)°íÇ÷¾Ð(ÍÔúìäâ)
  • hypertension
    °íÇ÷¾Ð(Áõ)(ÍÔúìäâñø), ±äÀåÇ×Áø(Áõ)(ÑÌíåùñòäñø).
  • hypertension
    °íÇ÷¾Ð(Áõ)(ÍÔúìäâ)
  • hypertension cranienne ºÒ
    ³ú¾ÐÇ×Áø(Áõ).
  • hypertension paroxystique ºÒ
    ¹ßÀÛ¼º °íÇ÷¾Ð(Áõ)(Û¡íÂàõÍÔúìäâñø).
  • hypertension,benign nephrosclerosis
    ¾ç¼º ½Å°æÈ­Áõ
  • hypertension,essential
    º»Å¼º(Üâ÷¾àõ)
  • hypertension,malignant
    ¾Ç¼º(äÂàõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PVC Premature Ventricular Contraction(s)
  = VEB
  ? Ix of Tx
  ...
NS natural science; Neosporin; nephrosclerosis; nephrotic syndrome; nervous system; neurological surger...
PSDES primary symptomatic diffuse esophageal spasm
SDES symptomatic diffuse esophageal spasm
SH Salter-Harris [fracture]; Schonlein-Henoch [purpura]; self-help; serum hepatitis; sexual harassment;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BIH Benign Intracranial Hypertension
BH Borderline hypertension
BHS British Hypertension Society
CT-E PH Chronic thromboembolic pulmonary hypertension
DASH Dietary Approaches to Stop Hypertension
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • splenoportal hypertension
    ºñ ¹®¸Æ¼º °íÇ÷¾ÐÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
symptomatic torticollis Stiff neck due to cervical or neck myositis, chiefly of the sternocleidomastoid, occurring especially in children.
Synonym: rheumatic torticollis.
(05 Mar 2000)
symptomatic treatment Therapy aimed at relieving symptoms without necessarily affecting the basic underlying cause(s) of the symptoms.
(05 Mar 2000)
symptomatic ulcer An ulcer due to systemic disease, such as tuberculosis.
Synonym: symptomatic ulcer.
(05 Mar 2000)
symptomatic varicocele A varicocele caused by obstruction of the internal spermatic vein, usually at the level of the renal vein and usually due to invasive renal cell carcinoma, characterised by failure of the dilated veins in the spermatic cord to empty when the patient assumes a recumbent position.
(05 Mar 2000)
accelerated hypertension <cardiology> A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
adrenal hypertension Hypertension due to an adrenal medullary pheochromocytoma or to hyperactivity or functioning tumour of the adrenal cortex.
(05 Mar 2000)
benign hypertension Hypertension that runs a relatively long and symptomless course.
(05 Mar 2000)
borderline hypertension By consensus, that blood pressure zone between highest acceptable "normal" blood pressure and hypertensive blood pressure. The Framingham Heart Study defines this as pressures between 140 and 160 mm Hg systolic and 90 and 95 mm Hg diastolic.
(05 Mar 2000)
pale hypertension Hypertension with pallor of the skin, a severe form with pronounced constriction of peripheral vessels.
(05 Mar 2000)
malignant hypertension A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
renal hypertension Hypertension secondary to renal disease.
(05 Mar 2000)
renovascular hypertension Hypertension produced by renal arterial obstruction.
(05 Mar 2000)
Goldblatt hypertension Increased blood pressure following obstruction of blood flow to one kidney.
Synonym: Goldblatt phenomenon.
(05 Mar 2000)
portal hypertension Any increase in the portal vein (in the liver) pressure due to anatomic or functional obstruction (for example alcoholic cirrhosis) to blood flow in the portal venous system. Indicators of portal hypertension are: oesophageal varices, haemorrhoids, enlarged veins on the anterior abdominal wall (caput Medusae) and ascites (fluid within the abdominal cavity).
(27 Sep 1997)
portal hypertension: classification <radiology> Presinusoidal, extrahepatic: portal vein obstruction (extrinsic compression, phlebitis, OC, coagulopathy, tumour invasion, pancreatitis, neonatal omphalitis), dynamic: traumatic/neoplastic arterioportal fistula, segmental portal hypertension: splenic/superior mesenteric vein occlusion, intrahepatic (obstruction of portal venules): congenital hepatic fibrosis, primary biliary cirrhosis, sarcoid, myelofibrosis, schistosomiasis, idiopathic noncirrhotic fibrosis, Wilson disease, reticuloendotheliosis, Felty syndrome, chronic malaria, toxic fibrosis (arsenic, copper, PVC vapors) sinusoidal, cirrhosis, sclerosing cholangitis postsinusoidal, Budd-Chiari syndrome, constrictive pericarditis, congestive heart failure
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á